Anagrelide – Thrombocythaemia

Drug Name (Brand)	Anagrelide ▼ *(Xagrid® ▼ / Agrelin® / Agrylin®)*
Indication	Thrombocythaemia
Traffic Light Classification	Amber shared care agreement
Link to SCA	SCAAnagrelide_PPMO_Nutrition_01032025.pdf
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. November 2012: Shared Care Agreement reviewed and available via http://nww.knowledgeanglia.nhs.uk/tag/shared_care/anagrelide_for_thrombocythaemia.htm. Shared care will continue subject to funds being transferred back from Trusts to cover primary care prescribing of this in-tariff treatment. November 2014: Minor changes to the shared care agreement were noted and supported. The TAG supported the continued use of the shared care agreement. November 2014: The NHS Norfolk & waveney CCGs D&TCG noted and supported the TAG recommendation. September 2017: The revised draft shared care agreement was reviewed and updated in line with the manufacturer’s SPCs. No further recommendations for changes were received from the authors / local specialists. The TAG supported its continued use and confirmed a classification of Amber (Option for GP prescribing under an approved shared care agreement). September 2017: The NHS Norfolk & Waveney CCGs’ D&TCG noted and supported the TAG recommendation.
Date of TAG recommendation / ratification		9/1/2017	Review Date